Bioteque
Bioteque Corporation manufactures and sells medical device in Asia, South America, North America, and internationally. The company provides medical disposables for use in hemodialysis access, endovascular treatment, and other fields. It offers dialysis products, including hemodialysis bloodlines, A.V.F. needles, and hemodialysis cathers; interventional radiology products, such as pigtail drainage… Read more
Bioteque (4107) - Total Assets
Latest total assets as of September 2025: NT$4.49 Billion TWD
Based on the latest financial reports, Bioteque (4107) holds total assets worth NT$4.49 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioteque - Total Assets Trend (2006–2024)
This chart illustrates how Bioteque’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bioteque - Asset Composition Analysis
Current Asset Composition (December 2024)
Bioteque's total assets of NT$4.49 Billion consist of 47.7% current assets and 52.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 26.6% |
| Accounts Receivable | NT$192.66 Million | 4.2% |
| Inventory | NT$320.70 Million | 6.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Bioteque's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioteque's current assets represent 47.7% of total assets in 2024, an increase from 43.0% in 2006.
- Cash Position: Cash and equivalents constituted 26.6% of total assets in 2024, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 6.9% of total assets.
Bioteque Competitors by Total Assets
Key competitors of Bioteque based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Bioteque - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Bioteque generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Bioteque generates $ 11.37 in net profit.
Bioteque - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.11 | 3.88 | 4.89 |
| Quick Ratio | 3.54 | 3.34 | 4.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.63 Billion | NT$ 1.52 Billion | NT$ 1.65 Billion |
Bioteque - Advanced Valuation Insights
This section examines the relationship between Bioteque's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.41 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | NT$4.65 Billion |
| Market Capitalization | $198.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioteque's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bioteque's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bioteque (2006–2024)
The table below shows the annual total assets of Bioteque from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$4.65 Billion | +0.54% |
| 2023-12-31 | NT$4.62 Billion | +3.12% |
| 2022-12-31 | NT$4.48 Billion | +16.05% |
| 2021-12-31 | NT$3.86 Billion | +8.34% |
| 2020-12-31 | NT$3.56 Billion | +21.20% |
| 2019-12-31 | NT$2.94 Billion | +6.10% |
| 2018-12-31 | NT$2.77 Billion | +5.72% |
| 2017-12-31 | NT$2.62 Billion | +2.25% |
| 2016-12-31 | NT$2.56 Billion | +2.40% |
| 2015-12-31 | NT$2.50 Billion | +6.69% |
| 2014-12-31 | NT$2.35 Billion | +17.52% |
| 2013-12-31 | NT$2.00 Billion | +22.78% |
| 2012-12-31 | NT$1.63 Billion | -0.11% |
| 2011-12-31 | NT$1.63 Billion | -3.37% |
| 2010-12-31 | NT$1.69 Billion | -2.44% |
| 2009-12-31 | NT$1.73 Billion | +0.31% |
| 2008-12-31 | NT$1.72 Billion | +4.28% |
| 2007-12-31 | NT$1.65 Billion | +26.11% |
| 2006-12-31 | NT$1.31 Billion | -- |